Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A 56-year-old woman with pulmonary complex disease was started on inhalation liposomal amikacin. One month later, she developed hoarseness and was diagnosed with laryngitis. The laryngitis healed immediately after treatment discontinuation, and no recurrence occurred even after resuming intermittent inhalation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859073 | PMC |
| http://dx.doi.org/10.1002/ccr3.5350 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pulmonary targeted delivery of ivacaftor liposomes for F508 del-CFTR mutation mediated cystic fibrosis therapy.
Int J Pharm
September 2025
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Raebareli Road, Lucknow 226025 Uttar Pradesh, India. Electronic address:
Cystic fibrosis (CF) is an autosomal recessive genetic disease elicited by mutations in the gene encoding the CF transmembrane conductance regulator protein (CFTR). Complications associated with CF include airway blockade leading to lung damage, respiratory tract infection, etc. Ivacaftor (IVA), also known as VX-770, works by potentiating the CFTR, leading to improved chloride transport and relieving lung pulmonary complications.
View Article and Find Full Text PDF[Development of Drug Delivery Systems Based on New Concepts].
Yakugaku Zasshi
August 2025
Department of Pharmaceutics and Drug Delivery, Faculty of Pharmaceutical Sciences, Tokyo University of Science.
This review is a partial summary of the author's 40 years of research and development at Otsuka Pharmaceutical Co., Ltd. and the Faculty of Pharmaceutical Sciences, Tokyo University of Science.
View Article and Find Full Text PDFLiposomal drug delivery system for lung diseases: Recent advancement and future perspectives.
Nanomedicine
August 2025
Centre for Inflammation, Faculty of Science, School of Life Sciences, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia; Woolcock Institute of Medical Research, Macquarie University, Sydney, New South Wales, Australia; Uttaranchal Institute of Pharmaceutical
Lung diseases such as asthma, chronic respiratory diseases, and lung cancer are among the most prevalent and vulnerable health conditions. Various therapeutic approaches, including nucleic acids, peptides, and small molecules have been developed along with different delivery strategies for their treatment. Liposomes have been recognized as promising delivery candidates attributed to their biocompatibility, biodegradability, and ability to encapsulate both hydrophilic and hydrophobic drugs effectively.
View Article and Find Full Text PDFLatest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.
Pharmaceutics
August 2025
Centro de Investigación en Alimentación y Desarrollo, A.C. Carretera a La Victoria Km. 0.6, Hermosillo 83304, Sonora, Mexico.
The concerning increase in respiratory infections that are resistant to multiple drugs has led to a growing interest in bacteriophage therapy as a potential alternative to conventional antibiotics. Effective phage delivery to the lungs, however, presents several formulation and stability issues, particularly for inhalation-based methods. This review highlights current developments in the creation of dry powder formulations that can be inhaled for pulmonary phage therapy, with a focus on encapsulation methods based on nanoparticles, such as solid lipid nanoparticles (SLNs) and polymer-based nanoparticles.
View Article and Find Full Text PDFInhalable Fibroin Hybrid Liposomes for the Targeted Treatment of Lung Adenocarcinoma via Autophagy-Enhanced Ferroptosis.
ACS Nano
August 2025
State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou 511443, P. R. China.
The application of ferroptosis inducer FIN56 to decrease antioxidant levels in lung adenocarcinoma (LUAD) is a promising tumor eradication technique. However, several obstacles reduce the efficacy of ferroptosis therapy including insufficient oxidative stress from monotherapy and restricted drug retention in tumor tissues. To address these challenges, we developed an inhalable hybrid liposome in which FIN56 and piperlongumine (PPL) are coloaded into silk fibroin nanoparticles to overcome the limitation of the poor therapeutic effect of single-drug ferroptosis.
View Article and Find Full Text PDF